Evolving Paradigms in the Detection and Treatment of Prostate Cancer

News
Video

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Related Videos
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Related Content
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024
Article
18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024
Article